Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.50
+0.06 (+0.42%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
May 31, 2022
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
May 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Celebrates World Quality Week
November 10, 2021
SOURCE: Takeda
Via
3BL Media
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
May 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
April 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
April 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
April 13, 2022
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...
Via
FinancialNewsMedia
Exposures
COVID-19
Takeda Announces Completion of Acquisition of Own Shares
April 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
April 12, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
April 05, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
March 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
February 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2
February 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
February 03, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
January 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Named Global Top Employer for Fifth Consecutive Year
January 19, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
January 10, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
December 21, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
December 21, 2021
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to...
Via
FinancialNewsMedia
Exposures
Product Safety
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
December 13, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
December 08, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting
December 07, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
December 02, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
November 30, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
November 23, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease
November 04, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.